Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

APYX DEADLINE: Pawar Law Group Reminds Investors of Deadline Securities Class Action Lawsuit Against Apyx Medical Corporation - APYX

APYX

NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Apyx Medical Corporation (NASDAQ: APYX) from August 1, 2018 through April 1, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages Apyx investors under the federal securities laws.  The firm reminds investors of the June 17, 2019 lead plaintiff deadline in the case.

To join the Apyx class action, go to http://pawarlawgroup.com/cases/apyx-medical-corporation/ or call Vik Pawar, Esq. or toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the clinical study on the use of J-Plasma, a plasma-based surgical product for cutting, coagulation, and ablation of soft tissue, for dermal resurfacing had not met its primary efficacy endpoint; (2) the clinical study did not support Apyx’s application for regulatory clearance; (3) Apyx was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing; and (4) as a result of the foregoing, Defendants’ positive statements about Apyx’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 17, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/apyx-medical-corporation/ or to discuss your rights or interests regarding this class action, please contact Vik Pawar, Esq. of Pawar Law Group toll free at 888-589-9804 or via e-mail at info@pawarlawgroup.com.

No class has been certified.  Until a class is certified, you are not represented by counsel unless you hire one.  You may hire counsel of your choice.  You may also do nothing at this time and be an absent member of the class.  Your ability to share in any future recovery is not dependent upon being a lead plaintiff. 

Pawar Law Group represents investors from around the world.
-------------------------------

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1210  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
info@pawarlawgroup.com  

Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today